Impacts of treatments on recurrence and 28-year survival of ischemic stroke patients.

Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE

Original Publication: London : Nature Publishing Group, copyright 2011-

Aged*; Brain Ischemia/*pathology ; Stroke/*pathology; Female ; Humans ; Middle Aged ; Recurrence ; Survival Rate

Aspirin and nicametate are well-established therapies for preventing recurrence and mortality from stroke in patients diagnosed as ischemic stroke. However, their respective effects on the recurrence, making allowance for the duration of recurrence and death without the occurrence of recurrence, and long-term survival have not been well elucidated. We aimed to evaluate long-term effect of two kinds of treatment on cerebrovascular death among ischemic stroke patients with or without the recurrence of stroke. Data used in this study were derived from the cohort based on a multicenter randomized double-blind controlled trial during 1992 to 1995 with the enrollment of a total of 466 patients with first-time non-cardioembolic ischemic stroke who were randomly allocated to receive aspirin (n = 222) or nicametate (n = 244). The trial cohort was followed up over time to ascertain the date of recurrence within trial period and death until Sep of 2019. The time-dependent Cox regression model was used to estimate the long-term effects of two treatments on death from cerebrovascular disease with and without recurrence. A total of 49 patients experienced stroke recurrence and 89 cerebrovascular deaths was confirmed. Patients treated with nicametate were more likely, but non statistically significantly, to have recurrence (aHR: 1.73, 95% CI 0.96-3.13) as compared with those treated by aspirin. Nicametate reduced the risk of cerebrovascular death about 37% (aHR: 0.63, 95% CI 0.41-0.97) compared with aspirin. The aspirin group had a lower recurrence rate than the nicametate group even with recurrence after 1-2 years of follow-up of first stroke but the latter had significantly reduced death from cerebrovascular disease for nicametate group, which requires more research to verify.
(© 2021. The Author(s).)

Thromb Res. 1997 Jul 15;87(2):215-24. (PMID: 9259112)
Cerebrovasc Dis. 2012;33(1):37-46. (PMID: 22133764)
Stroke. 2001 Sep;32(9):2131-6. (PMID: 11546907)
BMC Neurol. 2013 Oct 03;13:133. (PMID: 24088308)
Int J Epidemiol. 2003 Aug;32(4):563-72. (PMID: 12913030)
Stroke. 2014 Jul;45(7):2160-236. (PMID: 24788967)
Annu Rev Public Health. 1999;20:145-57. (PMID: 10352854)
BMJ Open. 2019 Dec 18;9(12):e032087. (PMID: 31857306)
Acta Neurol Scand. 2019 Jul;140(1):3-8. (PMID: 30929256)
Lancet Neurol. 2019 May;18(5):417-418. (PMID: 30871943)
N Engl J Med. 2018 Oct 18;379(16):1509-1518. (PMID: 30221597)
Arch Phys Med Rehabil. 2010 Jun;91(6):913-8. (PMID: 20510983)
Int J Stroke. 2018 Oct;13(8):787-796. (PMID: 30160619)
JAMA. 1998 Dec 9;280(22):1930-5. (PMID: 9851479)
Neurology. 2015 Sep 15;85(11):935-41. (PMID: 26296518)
Biometrics. 1983 Jun;39(2):499-503. (PMID: 6354290)
Stroke. 1997 Mar;28(3):557-63. (PMID: 9056611)
Int J Stroke. 2015 Oct;10 Suppl A100:89-95. (PMID: 26352280)
J Formos Med Assoc. 1990 Aug;89(8):635-44. (PMID: 1981223)
Arch Intern Med. 2002 Oct 28;162(19):2197-202. (PMID: 12390062)
Stroke. 1994 Feb;25(2):333-7. (PMID: 8303740)
Ann Neurol. 2006 Oct;60(4):469-75. (PMID: 16927332)
Lancet. 2016 Jul 23;388(10042):365-375. (PMID: 27209146)
Int J Epidemiol. 2000 Apr;29(2):336-43. (PMID: 10817134)
Stroke. 1982 May-Jun;13(3):290-5. (PMID: 7080120)
Thromb Res. 2000 Feb 1;97(3):95-103. (PMID: 10680640)
BMJ. 2002 Jan 12;324(7329):71-86. (PMID: 11786451)
BMC Nephrol. 2016 Sep 21;17(1):134. (PMID: 27655405)
J Stroke. 2016 Jan;18(1):60-5. (PMID: 26687123)
Stroke. 2003 Aug;34(8):1828-32. (PMID: 12855836)
Stroke. 2011 Jan;42(1):227-76. (PMID: 20966421)
Neurology. 1997 Apr;48(4):891-5. (PMID: 9109873)
Diabetes Care. 2009 Apr;32(4):617-22. (PMID: 19131465)
Stroke Vasc Neurol. 2017 Jul 6;2(4):176-183. (PMID: 29507777)
BMC Public Health. 2013 Jun 06;13:551. (PMID: 23742049)
Int J Stroke. 2020 Jan;15(1):9-17. (PMID: 31237833)
BMC Neurol. 2015 May 01;15:70. (PMID: 25927467)
Stroke. 2014 Sep;45(9):2670-6. (PMID: 25061076)
Circ J. 2020 May 25;84(6):943-948. (PMID: 32350232)
Cerebrovasc Dis. 2009;27(5):519-26. (PMID: 19372654)

Date Created: 20210728 Date Completed: 20211112 Latest Revision: 20211112

20231215

PMC8316573

10.1038/s41598-021-94757-6

34315990